- Non-inferior decreases in A1c levels;
- Significantly less hypoglycemia;
- Significant decreases in fasting blood glucose levels; and
- Significant weight advantage.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
MannKind (MNKD) is set to report 2016 second quarter results after Monday's market close.